Mother-child interaction and cognitive development in children prenatally exposed to methadone or buprenorphine.
To assess the influence of mother-child interaction on children's cognitive development in a group of children prenatally exposed to methadone or buprenorphine.



The study is part of a prospective longitudinal project investigating the development of children born to women in opioid maintenance therapy (OMT). The sample includes 67 children born between 2005 and 2007, 35 of which prenatally exposed to either methadone or buprenorphine and 32 non-exposed comparison children.



Both groups scored within the normal range of development. However, the OMT group scored significantly lower on measures of cognitive development and mother-child interaction compared to the comparison group. Cognitive development was found to be affected by both group status, F(1,54)=5.65, p=0.02, η(2)=0.10 and mother-child interaction F(1,54)=5.26, p=0.03, η(2)=0.09. Behavioral inhibition (statue), sensorimotor function (imitating hand positions), and short-term memory (sentences) was influenced by group status while narrative memory and vocabulary were found to be more influenced by mother-child interaction.



Different risk factors may influence different cognitive functions in children of women in OMT. Specifically, language-related cognitive skills may be more related to mother-child interaction while performance in higher cognitive functions requiring precise control over sensorimotor responses may be more sensitive to other factors such as prenatal OMT exposure, genetics, and/or prenatal exposure to other substances.
The Cognitive Developmental Research Unit, Department of Psychology, University of Oslo, Norway. Electronic address: caroliko@psykologi.uio.no.
Carolien
C
Konijnenberg
Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway.
Monica
M
Sarfi
The Cognitive Developmental Research Unit, Department of Psychology, University of Oslo, Norway.
Annika
A
Melinder
D000328:Adult; D002047:Buprenorphine / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D002657:Child Development / Q000187:drug effects*; D003071:Cognition; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007804:Language Development; D008297:Male; D008568:Memory; D008691:Methadone / Q000009:adverse effects* / Q000627:therapeutic use; D009034:Mother-Child Relations; D009292:Narcotic Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D058850:Opiate Substitution Treatment / Q000009:adverse effects; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000453:epidemiology*; D011597:Psychomotor Performance
D009292:Narcotic Antagonists; D002047:Buprenorphine; D008691:Methadone